Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Sponsor: MoonLake Immunotherapeutics AG
Summary
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Official title: Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
234
Start Date
2022-04-25
Completion Date
2023-08-30
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
Sonelokimab (M1095)
randomized treatment; parallel-group
Adalimumab
randomized treatment; parallel-group
Placebo
randomized treatment; parallel-group
Locations (57)
Clinical Site
Fountain Valley, California, United States
Clinical Site
Los Angeles, California, United States
Clinical Site
Miami, Florida, United States
Clinical Site
Ormond Beach, Florida, United States
Clinical Site
St. Petersburg, Florida, United States
Clinical Site
Tampa, Florida, United States
Clinical Site
Indianapolis, Indiana, United States
Clinical Site
Beverly, Massachusetts, United States
Clinical Site
Boston, Massachusetts, United States
Clinical Site
Omaha, Nebraska, United States
Clinical Site
New York, New York, United States
Clinical Site
Philadelphia, Pennsylvania, United States
Clinical Site
Charleston, South Carolina, United States
Clinical Site
Nashville, Tennessee, United States
Clinical Site
Bellaire, Texas, United States
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Calgary, Alberta, Canada
Clinical Site
Winnipeg, Manitoba, Canada
Clinical Site
Fredericton, New Brunswick, Canada
Clinical Site
St. John's, Newfoundland and Labrador, Canada
Clinical Site
Hamilton, Ontario, Canada
Clinical Site
London, Ontario, Canada
Clinical Site
Markham, Ontario, Canada
Clinical Site
Newmarket, Ontario, Canada
Clinical Site
Peterborough, Ontario, Canada
Clinical Site
Saskatoon, Saskatchewan, Canada
Clinical Site
Bad Bentheim, Germany
Clinical Site
Berlin, Germany
Clinical Site
Berlin, Germany
Clinical Site
Berlin, Germany
Clinical Site
Bochum, Germany
Clinical Site
Darmstadt, Germany
Clinical Site
Dresden, Germany
Clinical Site
Frankfurt, Germany
Clinical Site
Hamburg, Germany
Clinical Site
Kiel, Germany
Clinical Site
Lübeck, Germany
Clinical Site
Mahlow, Germany
Clinical Site
München, Germany
Clinical Site
Münster, Germany
Clinical Site
Dublin, Ireland
Clinical Site
Bergen op Zoom, Netherlands
Clinical Site
Rotterdam, Netherlands
Clinical Site
Gdansk, Poland
Clinical Site
Krakow, Poland
Clinical Site
Lodz, Poland
Clinical Site
Olsztyn, Poland
Clinical Site
Ossy, Poland
Clinical Site
Ostrowiec Świętokrzyski, Poland
Clinical Site
Poznan, Poland
Clinical Site
Warsaw, Poland
Clinical Site
Warsaw, Poland
Clinical Site
Wroclaw, Poland
Clinical Site
Wroclaw, Poland